247 related articles for article (PubMed ID: 9733480)
1. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
[No Abstract] [Full Text] [Related]
2. (Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation factor Xa.
Shaw KJ; Guilford WJ; Dallas JL; Koovakkaat SK; McCarrick MA; Liang A; Light DR; Morrissey MM
J Med Chem; 1998 Sep; 41(19):3551-6. PubMed ID: 9733479
[No Abstract] [Full Text] [Related]
3. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
4. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
5. Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031).
Light DR; Guilford WJ
Curr Top Med Chem; 2001 Jun; 1(2):121-36. PubMed ID: 11899248
[TBL] [Abstract][Full Text] [Related]
6. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
[TBL] [Abstract][Full Text] [Related]
7. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
[TBL] [Abstract][Full Text] [Related]
8. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.
Lu T; Markotan T; Coppo F; Tomczuk B; Crysler C; Eisennagel S; Spurlino J; Gremminger L; Soll RM; Giardino EC; Bone R
Bioorg Med Chem Lett; 2004 Jul; 14(14):3727-31. PubMed ID: 15203151
[TBL] [Abstract][Full Text] [Related]
9. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
[TBL] [Abstract][Full Text] [Related]
12. Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.
Imaeda Y; Kuroita T; Sakamoto H; Kawamoto T; Tobisu M; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
J Med Chem; 2008 Jun; 51(12):3422-36. PubMed ID: 18507371
[TBL] [Abstract][Full Text] [Related]
13. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
Katakura S; Nagahara T; Hara T; Iwamoto M
Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
[TBL] [Abstract][Full Text] [Related]
16. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.
Li YL; Fevig JM; Cacciola J; Buriak J; Rossi KA; Jona J; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Oct; 16(19):5176-82. PubMed ID: 16870435
[TBL] [Abstract][Full Text] [Related]
17. Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors.
Zbinden KG; Obst-Sander U; Hilpert K; Kühne H; Banner DW; Böhm HJ; Stahl M; Ackermann J; Alig L; Weber L; Wessel HP; Riederer MA; Tschopp TB; Lavé T
Bioorg Med Chem Lett; 2005 Dec; 15(23):5344-52. PubMed ID: 16213138
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
[TBL] [Abstract][Full Text] [Related]
19. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
[TBL] [Abstract][Full Text] [Related]
20. Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.
Haginoya N; Kobayashi S; Komoriya S; Hirokawa Y; Furugori T; Nagahara T
Bioorg Med Chem Lett; 2004 Jun; 14(11):2935-9. PubMed ID: 15125963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
